RAC2

Scientists have solved a cellular murder mystery nearly 25 years after the case went cold. Following a trail of evidence from fruit flies to mice to humans revealed that cannibalistic cells likely cause a rare human immunodeficiency. Now the discovery shows promise for enhancing an up-and-coming cancer treatment. Scientists have solved a cellular murder mystery nearly 25 years after the case went cold. Following a trail of evidence from fruit flies to mice to humans revealed that cannibalistic cells likely cause a rare human immunodeficiency. Now the discovery shows promise for enhancing an up-and-coming cancer treatment. "This paper takes us from very fundamental cell biology in a fly, to explaining a human disease and harnessing that knowledge for a cancer therapy," said UC Santa Barbara's Denise Montell. "Each one of those steps feels like a major discovery, but here they are, all in one paper." Researchers in Montell's lab published their findings in the Proceedings of the National Academy of Sciences and are now investigating the mechanisms and implications. An ancient gene The primary character in this story is a gene, Rac2, and the protein it encodes. Rac2 is one of three Rac genes in humans. "Rac is very ancient in evolution, so it must serve a fundamental function," said senior author Montell, Duggan Professor and Distinguished Professor of Molecular, Cellular, and Developmental Biology. Rac proteins help build a cell's scaffolding, called the cytoskeleton. The cytoskeleton is made of dynamic filaments that allow cells to maintain their shape or deform, as needed. In 1996, while studying a small group of cells in the fruit fly ovary, Montell determined that Rac proteins are instrumental in cell movement. Since then, it has become clear that Rac is a nearly universal regulator of cell motility in animal cells. Back in the '90s, she noticed that a hyperactive form of the Rac1 protein, expressed in only a few cells in a fly's egg chamber, destroyed the whole tissue. "Just expressing this active Rac in six to eight cells kills the entire tissue, which is composed of about 900 cells," explained lead author Abhinava Mishra, a project scientist in Montell's lab. Why did this happen? How does it work? "This was our 25-year-old cold case," Montell said. A few years ago, evidence began to mount implicating cell eating, also known as cannibalism, in tissue destruction. There's a step in normal fly egg development where certain cells similar to the border cells consume their neighbors because they are no longer needed. Indeed, cellular cannibalism is not as rare as you might expect: Millions of old red blood cells are eliminated from the human body this way every second. Rac2 is one component of the complex eating process. Rac helps the eating cell to envelop its target. The team was curious if a hyperactive form of the protein was causing border cells to prematurely consume their neighbors. For this to occur, the border cells need to recognize their targets, which requires a particular receptor. Indeed, when Mishra blocked this receptor, the border cells expressing activated Rac didn't consume their neighbors, and the egg chamber remained alive and healthy. "Our 25-year-old cold case was solved, and that was very satisfying for us," Montell exclaimed. "But this is a fairly niche area of Drosophila egg development." The implications would soon grow, though. A mysterious immune condition Around the time that her lab made their breakthrough, Montell caught wind of an intriguing study in the journal Blood. This paper found that three unrelated people suffering from recurrent infections had the exact same mutation, which hyperactivates Rac2, a Rac protein produced in blood cells. She suspected her lab's recent revelation in fruit flies might shed light on this enigma. The patients' mutation was just mildly activating, and yet it was enough that they all suffered from multiple infections and ultimately needed bone marrow transplants. Blood tests revealed that these patients had nearly no T cells, a specialized kind of white blood cells crucial to the immune system. The team at the National Institutes of Health inserted the Rac2 mutation into mice and found the same mysterious loss of T cells. They also found that the T cells with hyperactive Rac developed normally in the animals' bone marrow, and migrated to the thymus, where they continued to mature without incident. But then they just seemed to disappear. So, the paper ended with a mystery: what was causing the T cells to disappear? The authors of that journal study had noticed that many of the patients' neutrophils -- another type of white blood cell -- were enlarged. They seemed to be consuming quite a lot of material, unusual behavior in an otherwise healthy person. Montell wondered if the patients' T cells were disappearing because their innate immune cells like neutrophils with active Rac2 were eating them, much like the fruit fly border cells with active Rac were eating the egg chamber. Her team turned their attention to macrophages -- the neutrophil's more voracious counterpart -- to investigate. Mishra cultured human macrophages with and without hyperactive Rac2 together with T cells. He observed that macrophages with hyperactive Rac consumed more cells, confirming the group's hypothesis from their work with fruit flies. To test whether this might cause the observed immunodeficiency, co-author Melanie Rodriguez (a graduate student in Montell's lab) took bone marrow samples from mice with the same hyperactive Rac2 mutation found in the patients. She then grew the marrow stem cells into macrophages, and performed a similar experiment to Mishra, but this time mixing both macrophages and T cells with and without the Rac2 mutation. She found that macrophages with active Rac2 consumed significantly more T-cells than their normal counterparts. However, T-cells with active Rac2 were also more vulnerable to consumption from either kind of macrophage. So the most likely explanation for the patients' missing T cells was a combination of increased consumption by macrophages as well as increased vulnerability of the T cells themselves. A human medical mystery was solved based on fundamental observations in fruit flies. Harnessing haywire cells The implications of these insights expanded in January 2020, when co-author Meghan Morrissey interviewed for a faculty position at UCSB. In her talk she described programming macrophages to eat cancer cells as a novel treatment for the disease, an approach called CAR-M. Morrissey had found that adding a CAR receptor to macrophages promoted this behavior. But it was also clear that inducing the macrophages to eat more would make the approach more effective -- especially if they would specifically consume, and kill, entire cancer cells . Well, if there was one thing that Montell and her lab had learned, it was how to make macrophages eat and kill whole, living cells. So they collaborated with Morrissey, now an assistant professor of molecular, cellular and developmental biology, to determine if adding activated Rac2 would increase the effectiveness of the CAR-M approach. Rodriguez grew macrophages from the bone marrow of normal and mutant mice with activated Rac2. In each of these groups, Morrissey expressed either a dummy receptor or the CAR receptor, which recognizes B cells (another type of white blood cell). They found that the normal and hyperactive Rac cells with the dummy receptors did not eat many B cell targets. The normal macrophages with CAR receptors consumed far more B cells, as Morrissey had previously shown. However the macrophages with both hyperactive Rac and the CAR receptors ate twice-again as many B cells as the CAR-only group. Activated Rac2 also seemed to increase the number of so-called "super eaters" -- ravenous macrophages that eat and kill multiple cancer cells. The results made it clear that activated Rac and the receptor were both necessary for the enhanced effect. "If you add active Rac without the right receptor, it doesn't do anything," Montell explained. This level of control is good news for any potential treatments, because it would give doctors a way to focus the modified macrophages' attack on cancerous cells. Clinicians hopefully won't need to worry about the engineered cells eating the patient's T-cells either, because the T-cells wouldn't have the active Rac2 mutation making them more vulnerable to this, as Rodriguez had previously discovered. There is a current cancer treatment called CAR-T, which uses the CAR receptor and a patient's own T-cells to attack and destroy cancers. It is highly effective against some cancers, but there are many that do not respond. CAR-M,a newer cousin to CAR-T, has recently entered into clinical trials in humans and so far seems safe. Montell and her group are interested in harnessing Rac-enhanced CAR macrophages to increase the efficacy of CAR-M treatments. They've filed a provisional patent for the technique -- which they call RaceCAR-M -- and are inviting biotech companies to partner in further developing the approach. This new multifaceted paper raises both basic science and practical questions, which the lab has begun to tackle. They're investigating whether the technique, which is so effective in the lab, will also work in freshly collected human immune cells and in animal cancer models, in mice and zebrafish. The team is also exploring how Rac2 is making this all happen at the molecular level, deep inside the cells. Further down the line, Montell wants to know how many kinds of cancer the RaceCAR-M treatment might successfully target. For comparison, CAR-T has been effective against cancers like leukemia and lymphoma, but not against solid-tumor cancers like breast, lung or colon. The results have amazed Montell, an esteemed cell biologist with well over 100 papers to her name. "This is my favorite paper so far," she said. "We had this 25-year-old cold case in fruit flies, and we solved it," Montell added. "And that helped us solve the mystery of an unexplained human immunodeficiency. And then we harnessed that knowledge to enhance a potential cancer immunotherapy. "It was just one mystery after another, and Rac turned out to be the answer to each of them." You can hear more about the path from fruit flies to potential cancer treatment in Montell's SNPets interview with the Genetics Society of America, episodes 4-6 ( ).

RAS is a small G protein composed of 188 amino acids, primarily distributed on the inner membrane of the cytoplasm in cells, its activity undergoes dynamic changes. When RAS is bound to GDP, it is in an inactive state, however, when RAS binds with GTP, it is in an activated state, thereby promoting the activation of a variety of downstream signaling pathways, such as MAPK, PI3K, RAF, etc. A variety of RAS mutations can cause it to be constantly in an active state, such overactivation promotes the development of cancer, thus RAS inhibitors can be regarded as a sharp sword to inhibit tumors. RAS protein has three subtypes, KRAS, HRAS, NRAS, among which the frequency of KRAS mutations accounts for 85% of the total number of RAS mutations, NRAS accounts for 11%, and HRAS only 4%. The most common mutation in KRAS is the G12 mutation, including G12D, G12C, G12V. Research shows that these mutations can cause RAS to be constantly bound to GTP, and remain in an active state. Various data websites all show that RAS mutations can promote the development of many types of tumors. Although the carcinogenic mechanism of KRAS is relatively clear, KRAS was deemed "undruggable" because it has no obvious binding sites in its structure, and research on inhibitors that directly target KRAS did not make any breakthroughs for a long time. Ras Competitive LandscapeAccording to the data provided by Patsnap Synapse-Global Drug Intelligence Database: the following figure shows that as of 25 Sep 2023, there are a total of 279 Ras drugs worldwide, from 217 organizations, covering 71 indications, and conducting 250 clinical trials. 👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs , indications, organizations, clinical trials, clinical results, and drug patents related to this target. The current competitive landscape of target Ras in the pharmaceutical industry is characterized by the involvement of multiple companies, with Mirati Therapeutics, Inc., Amgen, Inc., and Novartis AG leading the way in terms of R&D progress. The indications for drugs targeting Ras cover a wide range of cancers, indicating the potential for these therapies in various tumor types. Small molecule drugs are the most rapidly progressing drug type, with intense competition from biosimilars. The United States, China, and European Union are the key locations driving the development of drugs targeting Ras, with China showing significant progress. Overall, the future development of target Ras in the pharmaceutical industry holds promise for innovative therapies and potential advancements in cancer treatment. Key drug:SotorasibSotorasib is a small molecule drug developed by Amgen, Inc. It falls under the category of biomedicine and is primarily used to target KRAS G12C, a specific mutation found in various types of cancers. The drug has shown potential therapeutic benefits in the treatment of neoplasms, digestive system disorders, and respiratory diseases. 👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug. Sotorasib's active indications include advanced lung non-small cell carcinoma, KRAS G12C mutant non-small cell lung cancer, non-small cell lung cancer, KRAS p.G12C mutant colorectal cancer, colorectal cancer, and solid tumors. These indications highlight the drug's potential in treating a wide range of cancer types, particularly those associated with the KRAS G12C mutation. The highest phase of development for Sotorasib is approved globally, indicating that it has successfully completed clinical trials and received regulatory approval for commercial use. In China, the drug is currently in phase 3 of development, suggesting that it is undergoing further testing and evaluation in that market. Sotorasib received its first approval in the United States in May 2021, making it available for use in the treatment of eligible patients. The drug has been granted several regulatory designations, including fast track, breakthrough therapy, accelerated approval, and orphan drug status. These designations signify the potential of Sotorasib to address unmet medical needs and expedite its development and availability for patients. In summary, Sotorasib is a small molecule drug developed by Amgen, Inc. that targets the KRAS G12C mutation. It has shown promise in treating various types of cancers, including advanced lung non-small cell carcinoma and colorectal cancer. With its recent approval in the United States and ongoing phase 3 development in China, Sotorasib represents a significant advancement in the field of biomedicine for the treatment of specific cancer mutations. MRTX-1133MRTX-1133 is a small molecule drug developed by Mirati Therapeutics, Inc. It falls under the category of biomedicine and is primarily designed to target the KRAS G12D mutation. This mutation is associated with various types of cancers, including colorectal cancer, non-small cell lung cancer, and pancreatic adenocarcinoma. 👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug. The therapeutic areas in which MRTX-1133 is expected to be effective include neoplasms, digestive system disorders, endocrinology and metabolic diseases, and respiratory diseases. These areas encompass a wide range of conditions, highlighting the potential versatility of this drug. The active indications for MRTX-1133 include colorectal cancer with the KRAS G12D mutation, non-small cell lung cancer with the KRAS G12D mutation, pancreatic adenocarcinoma with the KRAS G12D mutation, colorectal cancer, solid tumors with the KRAS G12D mutation, non-small cell lung cancer, pancreatic adenocarcinoma, neoplasms, and pancreatic cancer. This suggests that MRTX-1133 has the potential to be used in the treatment of various cancers, particularly those associated with the KRAS G12D mutation. Currently, MRTX-1133 is in Phase 1/2 of development. This indicates that the drug has undergone initial testing in humans and is now being further evaluated for its safety and efficacy. Phase 1/2 trials typically involve a small number of participants and aim to determine the appropriate dosage and potential side effects of the drug. In summary, MRTX-1133 is a small molecule drug developed by Mirati Therapeutics, Inc. It targets the KRAS G12D mutation and has potential applications in the treatment of various cancers, including colorectal cancer, non-small cell lung cancer, and pancreatic adenocarcinoma. The drug is currently in Phase 1/2 of development, indicating that it is undergoing further evaluation for its safety and effectiveness.

To learn more about what causes the body to reject biomedical implants, a team has identified a protein that appears to help drive this response and hopes their discoveries will improve the design and safety of biomedical implants. To learn more about what causes the body to reject biomedical implants, a team at the University of Arizona College of Medicine -- Tucson identified a protein that appears to help drive this response and hopes their discoveries will improve the design and safety of biomedical implants. The findings were published today in Nature Biomedical Engineering. Biomedical implants, such as breast implants, pacemakers and orthopedic hardware, have transformed medicine, but a significant number are rejected by the body and need to be removed. The culprit is a little-understood immune reaction called foreign body response, or FBR, in which the body encapsulates the implant in scar tissue. Senior author Geoffrey Gurtner, MD, FACS, department chair of surgery, and co-lead author Kellen Chen, PhD, assistant research professor of surgery, say their proposed approach is a departure from the conventional thought process for tackling implant failure, which thus far has relied on using so-called biocompatible materials that are better tolerated by the body but don't completely remove the risk of FBR. To understand why some immune systems build thick capsules around implants while others do not, the team gathered capsule samples from 20 patients whose breast implants were removed -- 10 whose reactions were severe, and 10 whose reactions were mild. A protein called RAC2 was highly expressed in samples taken from patients with severe reactions. "When we examined the severe fibrotic samples, RAC2 was one of the most important proteins we found," Chen said. "Because it seemed to drive a lot of downstream pathways, we decided to explore a little more closely." In reaction to mechanical stress caused by the implants, immune cells activate RAC2 and other proteins, which summon additional immune cells, including types that can combine to attack a large invader. "That foreign body, which is very stiff and causes stress on the external environment, activates these immune cells to aggregate to that area," Chen said. "They start merging with each other, making massive cells that spit out fibrous proteins like collagen and other products." To confirm RAC2's role in FBR, the team blocked the expression of RAC2 in animal models. "We targeted RAC2 along with other pathways and observed a significant reduction in the level of FBR -- up to three-fold," said Dharshan Sivaraj, research fellow in the Department of Surgery and co-lead author of the study. "We think targeting these pathways could serve as a potential therapy to mitigate or even prevent clinically significant FBR in humans." RAC2 is specific to immune cells, which means that, theoretically, a drug blocking it might only target immune cells without affecting other cells in the body. Gurtner and Chen, who are also members of the UArizona Cancer Center, say the next step is to create a more specific version of this drug ready for human use, and their team is already working with the Arizona Center for Drug Discovery at the R. Ken Coit College of Pharmacy to develop it. "We believe that local targeted therapy is better. Maybe there are ways to conjugate this drug onto an implant with some sort of coating to minimize systemic problems," Gurtner said. Tech Launch Arizona, the University of Arizona's technology commercialization office, is working with the team to translate the innovation from the laboratory to the marketplace, where they hope it will have real-world impact for patients and their health care providers. The Gurtner Lab conducted this study in collaboration with teams at Stanford University School of Medicine, the University of Texas Southwestern Medical Center, and University Hospital Regensburg in Germany. Other College of Medicine -- Tucson Department of Surgery authors included Hudson C. Kussie, research professional; Katharina Fischer, MD, postdoctoral fellow; and Artem A. Trotsyuk, PhD, assistant research professor. "Establishing a complete understanding of the molecular mechanisms driving the foreign body response presents the final frontier in developing truly bio-integrative medical devices," Gurtner said. The causes of FBR are relatively unknown. Chen said the prevailing hypothesis is that FBR is a reaction to the chemical composition of the implant. In contrast, this study demonstrates that the implant introduces stress points to the body, triggering an overactive immune response. "The cells touch this new material similar to if I touch something soft versus something hard. My body can tell that a table is harder than a pillow -- touching the table activates mechanical pathways in my fingers. Similarly, as the cells interact with that implant and surrounding tissue, they activate due to the increased mechanical stress," Chen said. "The immune cells realize there is a foreign body there, and they react by building a fibrotic capsule that surrounds the implant in an attempt to shield it off." The more severe the immune reaction, the thicker the capsule. In some people, this capsule constricts around the implant, impeding its function and causing pain. Up to 30% of implants need to be removed due to FBR.